Idebenone
From Wikipedia, the free encyclopedia
 |
This article requires authentication or verification by an expert. Please assist in recruiting an expert or improve this article yourself. See the talk page for details. (October 2008) |
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (October 2008) |
 |
|
|
Idebenone
|
|
| Systematic (IUPAC) name | |
| 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl- cyclohexa-2,5-diene-1,4-dione |
|
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C19H30O5 |
| Mol. mass | 338.439 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 18 hours |
| Excretion | urine and feces |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Idebenone (pronounced eye-deb-eh-known) is an organic compound of the quinone family and promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10).
Idebenone is claimed to have properties similar to CoQ10 in its antioxidant properties.[specify] Idebenone is a synthetic analogue of coenzyme Q10 used in Europe in the treatment of vascular and degenerative diseases of the central nervous system.
Research on idebenone as a potential therapy of Alzheimer's disease have been inconsistent, but there may be a trend for a slight benefit. Idebenone may benefit those with Friedreich's ataxia.
It inhibits lipoperoxide.[1]
Contents |
[edit] Uses
Idebenone has been used in the treatment of Friedreich's ataxia.[2][3] In a one-year test on eight patients, idebenone reduced the rate of deterioration of cardiac function in patients with Friedreich's ataxia, but without halting the progression of ataxia.[4]
Idebenone has also been used in topical applications to treat wrinkles.[5]
[edit] History
On July 23, 2008, Health Canada issued a Notice of Compliance under the Notice of Compliance with Conditions (NOC/c) Policy to Santhera Pharmaceuticals (Switzerland) Ltd. for the drug product Catena. The product was authorized under the NOC/c Policy on the basis of the promising nature of the clinical evidence, and the need for a confirmatory study to verify its clinical benefit. Patients should be advised of the fact that the market authorization was issued with conditions.
[edit] See also
- Free-radical theory of aging
[edit] References
- ^ Suno M, Nagaoka A (May 1988). "[Effect of idebenone and various nootropic drugs on lipid peroxidation in rat brain homogenate in the presence of succinate]" (in Japanese). Nippon Yakurigaku Zasshi 91 (5): 295–9. PMID 3410376.
- ^ Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (October 2007). "Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial". Lancet Neurol 6 (10): 878–86. doi:. PMID 17826341. http://linkinghub.elsevier.com/retrieve/pii/S1474-4422(07)70220-X.
- ^ Tonon C, Lodi R (September 2008). "Idebenone in Friedreich's ataxia". Expert Opin Pharmacother 9 (13): 2327–37. doi:. PMID 18710357. http://www.expertopin.com/doi/abs/10.1517/14656566.9.13.2327.
- ^ Buyse G, Mertens L, Di Salvo G, et al. (May 2003). "Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring". Neurology 60 (10): 1679–81. PMID 12771265. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12771265.
- ^ McDaniel D, Neudecker B, Dinardo J, Lewis J, Maibach H (September 2005). "Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone". J Cosmet Dermatol 4 (3): 167–73. doi:. PMID 17129261.
|
||||||||||||||||||||||||||||
